About Retinol dehydrogenase 5
Retinol dehydrogenase 5 (RDH5) is a protein
from Homo sapiens identified by UniProt accession
Q92781, 318 residues long.
MolForge cross-references it against 0 known binders and
69 disease associations.
Target properties
| Protein name | Retinol dehydrogenase 5 |
|---|
| UniProt accession | Q92781 |
|---|
| Gene | RDH5 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 318 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (3)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (69)
Diseases linked to this target (Open Targets).
- fundus albipunctatus · score 0.83
- congenital stationary night blindness · score 0.50
- Retinal dystrophy · score 0.44
- RDH5-related retinopathy · score 0.37
- Myopia · score 0.35
- refractive error · score 0.34
- retinitis punctata albescens · score 0.33
- self reported educational attainment · score 0.28
- Hypermetropia · score 0.28
- age at onset · score 0.28
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q92781-F1 | alphafold | PREDICTED | 96.06 | — |
Amino-acid sequence (318 residues)
MWLPLLLGAL LWAVLWLLRD RQSLPASNAF VFITGCDSGF GRLLALQLDQ RGFRVLASCL TPSGAEDLQR VASSRLHTTL LDITDPQSVQ QAAKWVEMHV KEAGLFGLVN NAGVAGIIGP TPWLTRDDFQ RVLNVNTMGP IGVTLALLPL LQQARGRVIN ITSVLGRLAA NGGGYCVSKF GLEAFSDSLR RDVAHFGIRV SIVEPGFFRT PVTNLESLEK TLQACWARLP PATQAHYGGA FLTKYLKMQQ RIMNLICDPD LTKVSRCLEH ALTARHPRTR YSPGWDAKLL WLPASYLPAS LVDAVLTWVL PKPAQAVY
Explore Retinol dehydrogenase 5 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets